(Q37946750)

25 August 2017

title

Continuing pursuit for ideal systemic anticancer radiotherapeutics (English)

1 reference

25 August 2017

Peter de Witte

6

0 references

author name string

Marlein Miranda Cona

1

1 reference

25 August 2017

Huaijun Wang

2

1 reference

25 August 2017

Junjie Li

3

1 reference

25 August 2017

Yuanbo Feng

4

1 reference

25 August 2017

Feng Chen

5

1 reference

25 August 2017

Alfons Verbruggen

7

1 reference

25 August 2017

Yicheng Ni

8

1 reference

25 August 2017

publication date

18 October 2011

1 reference

Investigational New Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

30

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

2050-2065

1 reference

Exploring multifunctional features of necrosis avid contrast agents

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

A dual-targeting anticancer approach: soil and seed principle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

A review of the general aspects of radiofrequency ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Chemical radiosensitizers for use in radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Tumour therapy with radionuclides: assessment of progress and problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Metaiodobenzylguanidine (mIBG) in treatment of 47 patients with neuroblastoma: results of the German Neuroblastoma Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Clinical review: Current treatment of malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Treatment of the myeloproliferative disorders with 32P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Systemic radionuclide therapy in pain palliation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Three-Dimensional Structure of Immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

The Role of the Intrachain Disulfide Bond in the Conformation and Stability of the Constant Fragment of the Immunoglobulin Light Chain1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Amino acid sequence of the Fv region of a human monoclonal IgM (protein WEA) with antibody activity against 3,4-pyruvylated galactose in Klebsiella polysaccharides K30 and K33

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Complement and Fc-receptors in regulation of the antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Tumour-associated antigens: considerations for their use in tumour immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Transport of molecules across tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Overview of monoclonal antibodies in cancer therapy: present and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Antibody-targeted radiation cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Natural and designer binding sites made by phage display technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Yeast display of antibody fragments: a discovery and characterization platform.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

In-vitro protein evolution by ribosome display and mRNA display

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Engineered antibody fragments and the rise of single domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

The hydrolysis of rabbit y-globulin and antibodies with crystalline papain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

"Diabodies": small bivalent and bispecific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Single-chain Fv multimers of the anti-neuraminidase antibody NC10: the residue at position 15 in the V(L) domain of the scFv-0 (V(L)-V(H)) molecule is primarily responsible for formation of a tetramer-trimer equilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Applications of single-chain variable fragment antibodies in therapeutics and diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Potent enzyme inhibitors derived from dromedary heavy-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Monoclonal antibodies as innovative therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Development trends for therapeutic antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pre-targeted immunodetection in glioma patients: tumour localization and single-photon emission tomography imaging of [99mTc]PnAO-biotin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Advances in pretargeting biotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pretargeting with the affinity enhancement system for radioimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Peptide receptors as molecular targets for cancer diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Receptor targeting for tumor localisation and therapy with radiopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Clinical results of long-term slow-release lanreotide treatment of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Somatostatin and its receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Neuroendocrine gastrointestinal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Neuropeptides as autocrine growth factors in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiolabeled peptides in oncology: role in diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Design, synthesis, and conformation of superpotent and prolonged acting melanotropins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

FDG-PET imaging for the staging and follow-up of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiation-induced DNA double-strand break rejoining in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiation for palliation--part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Relative biological effectiveness of accumulated 125IdU and 125I-estrogen decays in estrogen receptor-expressing MCF-7 human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiohalogens for imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Zur Kenntnis der Metalle der seltenen Erden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

The synthesis and chelation chemistry of DOTA-peptide conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Genetic neurodegenerative diseases: the human illness and transgenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

The clonal evolution of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Porphyrins as contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Necrosis avid contrast agents: functional similarity versus structural diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Pharacine, a natural p-cyclophane and other indole derivatives from Cytophaga sp. strain AM13.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

A potent cyclic hexapeptide analogue of somatostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9758-6

Triabodies: single chain Fv fragments without a linker form trivalent trimers

21 January 2018

1 reference

12 December 2020

Recent developments in 99Tcm-labelled peptide-based radiopharmaceuticals: an overview

1 reference

12 December 2020

Somatostatin receptors

1 reference

12 December 2020

Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease

1 reference

12 December 2020

Cancer as an evolutionary and ecological process

1 reference

12 December 2020

Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins

1 reference

12 December 2020

Pretargeted radioimmunotherapy of cancer: progress step by step

1 reference

12 December 2020

Targeted therapy of cancer with radiolabeled antibodies

1 reference

12 December 2020

Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging

1 reference

12 December 2020

Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings

1 reference

12 December 2020

Patterns of cell death.

1 reference

12 December 2020

Radiation for palliation--part 1

1 reference

12 December 2020

Apoptosis and necrosis: two types of cell death in alcoholic liver disease.

1 reference

12 December 2020

Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent

1 reference

12 December 2020

Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy

1 reference

12 December 2020

Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody

1 reference

12 December 2020

Yttrium-90-labelled somatostatin-analogue for cancer treatment

1 reference

12 December 2020

Monoclonal antibody hapten radiopharmaceutical delivery

1 reference

12 December 2020

Photodynamic therapy in the treatment of malignancies.

1 reference

12 December 2020

Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention

1 reference

12 December 2020

Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model

1 reference

12 December 2020

Detection of tumor-specific antigens in Philadelphia chromosome positive leukemias

1 reference

12 December 2020

Necrosis-avid contrast agents: introducing nonporphyrin species

1 reference

12 December 2020

1 reference

12 December 2020

Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: a preliminary study

1 reference

12 December 2020

Small peptides radiolabeled with 99mTc.

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.

1 reference

12 December 2020

Optimal conditions for the preparation of proteolytic fragments from monoclonal IgG of different rat IgG subclasses

1 reference

12 December 2020

Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha

1 reference

12 December 2020

Nuclear localizing sequences: an innovative way to improve targeted radiotherapy.

1 reference

12 December 2020

Transport of molecules in the tumor interstitium: a review

1 reference

12 December 2020

Radiobiologic principles in radionuclide therapy

1 reference

12 December 2020

Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate

1 reference

12 December 2020

Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue

1 reference

12 December 2020

Use and risks of phosphorus-32 in the treatment of polycythaemia vera

1 reference

12 December 2020

Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose

1 reference

12 December 2020

Tolerance of normal tissue to therapeutic irradiation

1 reference

12 December 2020

Radioimmunotherapy of cancer: arming the missiles

1 reference

12 December 2020

Radioimmunotherapy against the tumor vasculature: A new target?

1 reference

12 December 2020

Somatostatin analogue scintigraphy. A simple and sensitive method for the in vivo visualization of Merkel cell tumors and their metastases

1 reference

12 December 2020

Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer

1 reference

12 December 2020

Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept.

1 reference

12 December 2020

Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.

1 reference

12 December 2020

Comparative thermodynamic analyses of the Fv, Fab* and Fab fragments of anti-dansyl mouse monoclonal antibody

1 reference

12 December 2020

Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase.

1 reference

12 December 2020

Avidin and streptavidin

1 reference

12 December 2020

In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate

1 reference

12 December 2020

Single-chain antigen-binding proteins

1 reference

12 December 2020

Advances in the use of monoclonal antibodies in cancer radiotherapy

1 reference

12 December 2020

Porphyrin localization: A new modality for detection and therapy of tumors

1 reference

12 December 2020

Curative cancer chemotherapy

1 reference

12 December 2020

Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support

1 reference

12 December 2020

Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

1 reference

12 December 2020

Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.

1 reference

12 December 2020

Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

1 reference

12 December 2020

10.1007/S10637-011-9758-6

Identifiers

DOI

1 reference

25 August 2017

1 reference